BIG PHARMA has the BIG BUCKS. Little Pharma needs much more. Only Hours to go in this campaign.

We hoped that Crowdfunding might be a way to raise capital to help build the infrastructure that LITTLE PHARMA needs to serve up effective, safe, high-quality treatments using the enormous pharmacopeia that exist as generics. The visibility that Crowdfunding through NetCapital and StartEngine has given OneFul Health Inc has helped us get the message out that personalized, affordable medicine is coming with the aid of the type of technology that made the laser printer and the personal computer ubiquitous. We will continue to spread our message, and we are encouraged by the connections we have made with many types of investors, who are now keeping an eye on our progress, and we know will someday be our partners.

We thank the nearly 200 small investors who have invested in our vision.

Democratize Chronic Disease Treatments by Investing in Robotic Automation of Compounding Pharmacy!

Preventative Cardiovascular PolyPills Now – For Alzheimer’s and Dementia – Someday Soon? Why Is It So Hard to Treat Alzheimer’s? “The brain disease has long stymied researchers. But that has begun to change, and for the first time, ways to prevent, slow and even treat the disease are emerging “(https://www.aarp.org/health/conditions-treatments/info-2024/why-is-there-no-cure-for-alzheimers.html)

Cardiovascular diseases, including conditions like hypertension and diabetes, are linked to an increased risk of dementia, as poor cardiovascular health can lead to brain changes that contribute to cognitive decline.

OneFul Health is working with researchers who believe that a combination polypill may provide an affordable approach based on early detection home kit.

See article attached.

Better than GLP-1 Drugs: Are Endogenous GLP-1 Medical Foods Possible? OneFul possesses technologies that enable the delivery of high doses of active ingredients to specific regions of the digestive system. Using a patent pending method of micro-encapsulation, OneFul can capture active ingredients, including short-chain fatty acids (‘SCFA’s’), and some amino acids that have been shown in multiple research publications to stimulate GLP-1 and other satiety hormones, naturally. OneFul is exploring the development of complementary treatments to the GLP-1 agonists drugs, based on recent GLP-1 incretin science. It has the proven manufacturing systems that can personalize formulations to best match and individual’s metabolism, with products adapt to the young and old medical needs.

Revolutionizing Healthcare with Cutting-Edge Technology: Despite remarkable strides in computation, genomics, robotics, and Artificial Intelligence, the battle against global health challenges remains incomplete. Noncommunicable diseases claim 41 million lives annually, accounting for a staggering 74% of all deaths worldwide. Heart attacks, strokes, diabetes, and obesity—these silent killers drain healthcare resources and hinder human potential. And yet, the science is clear that there are low cost, effective means of prevention.

See recent article by Edison Hudson on OneFul’s thoughts and plans in metabolic and weight loss markets. https://www.linkedin.com/feed/update/urn:li:activity:7147705277612519424/

OneFul has begun to expand its cardio-metabolic products beyond the CVD polypill to include diabetes and obesity prevention, addressing the exploding market for such medications (link). Our accredited pharmaceutical facility, TriangleCompounding.com, is now filling prescriptions for FDA-approved form of semaglutide, the active ingredient of popular drugs Ozempic and Wegovy. In November, we completed the buy-back of Panaceutics.com, a supplier of personalized nutrition and clinical foods. This will enable us to offer personalized medical foods and clinical products through licensed prescriber channels. For example, Panaceutics has supplied squeeze pouch products serving gut health with specialized ingredients that create small-chain fatty acids, known to naturally stimulate GLP-1, the same hormone mimicked by the injected drugs. OneFul has begun the development of GLP-OneFul™, a personalized GLP-1 agonist oral product. We plan to use some of the NC funding to support a 2024 pilot.